tranexamic acid has been researched along with Placenta Increta in 6 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Placenta Increta: Invasion of CHORIONIC VILLI occurs deep into the MYOMETRIUM.
Excerpt | Relevance | Reference |
---|---|---|
"This study was a pre- and postimplementation analysis of concomitant uterine artery embolization and tranexamic acid in cases of patients with antenatally suspected placenta increta and percreta over a 5-year period (2018-2022)." | 8.31 | Implementation and outcomes of a uterine artery embolization and tranexamic acid protocol for placenta accreta spectrum. ( Blankenship, LM; McCann, GA; Munoz, JL; Ramsey, PS, 2023) |
"Bleeding was successfully treated using the antifibrinolytic agent tranexamic acid." | 5.42 | Tranexamic Acid for Hyperfibrinolytic Hemorrhage During Conservative Management of Placenta Percreta. ( Gembruch, U; Merz, WM; Pötzsch, B; Rühl, H; Schröder, L, 2015) |
"This study was a pre- and postimplementation analysis of concomitant uterine artery embolization and tranexamic acid in cases of patients with antenatally suspected placenta increta and percreta over a 5-year period (2018-2022)." | 4.31 | Implementation and outcomes of a uterine artery embolization and tranexamic acid protocol for placenta accreta spectrum. ( Blankenship, LM; McCann, GA; Munoz, JL; Ramsey, PS, 2023) |
" A rapid recourse to prostaglandins (sulprostone in France) may reverse uterine atony." | 3.83 | Major obstetric hemorrhage. ( Le Gouez, A; Mercier, FJ, 2016) |
"Bleeding was successfully treated using the antifibrinolytic agent tranexamic acid." | 1.42 | Tranexamic Acid for Hyperfibrinolytic Hemorrhage During Conservative Management of Placenta Percreta. ( Gembruch, U; Merz, WM; Pötzsch, B; Rühl, H; Schröder, L, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Munoz, JL | 1 |
Blankenship, LM | 1 |
Ramsey, PS | 1 |
McCann, GA | 1 |
Neely, D | 1 |
Elnour, S | 1 |
Schröder, L | 1 |
Pötzsch, B | 1 |
Rühl, H | 1 |
Gembruch, U | 1 |
Merz, WM | 1 |
Mauritz, AA | 1 |
Dominguez, JE | 1 |
Guinn, NR | 1 |
Gilner, J | 1 |
Habib, AS | 1 |
Le Gouez, A | 1 |
Mercier, FJ | 1 |
As, AK | 1 |
Hagen, P | 1 |
Webb, JB | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491] | Phase 3 | 11,000 participants (Actual) | Interventional | 2018-03-15 | Completed | ||
Efficacy of Tranexamic Acid in Reducing Blood Loss During and After Caesarean Section[NCT02350179] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2014-06-30 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum
Intervention | grams per deciliter (Mean) |
---|---|
Tranexamic Acid | -1.8 |
Placebo | -1.9 |
Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days
Intervention | days (Median) |
---|---|
Tranexamic Acid | 3 |
Placebo | 3 |
(NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 35 |
Placebo | 32 |
This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 108 |
Placebo | 109 |
This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 233 |
Placebo | 231 |
[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 892 |
Placebo | 986 |
Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 20 |
Placebo | 19 |
This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 29 |
Placebo | 31 |
This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 649 |
Placebo | 732 |
[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 12 |
Placebo | 13 |
[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 339 |
Placebo | 368 |
Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 201 |
Placebo | 233 |
[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 162 |
Placebo | 125 |
This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 2 |
Placebo | 0 |
6 other studies available for tranexamic acid and Placenta Increta
Article | Year |
---|---|
Implementation and outcomes of a uterine artery embolization and tranexamic acid protocol for placenta accreta spectrum.
Topics: Blood Transfusion; Cesarean Section; Hysterectomy; Placenta Accreta; Postpartum Hemorrhage; Pregnanc | 2023 |
Anaesthesia for abnormally invasive placenta: cell salvage and tranexamic acid.
Topics: Anesthesia; Anesthesiology; Antifibrinolytic Agents; Female; Humans; Placenta; Placenta Accreta; Pre | 2017 |
Tranexamic Acid for Hyperfibrinolytic Hemorrhage During Conservative Management of Placenta Percreta.
Topics: Adult; Antifibrinolytic Agents; Female; Fibrinolysis; Hemorrhage; Humans; Placenta Accreta; Pregnanc | 2015 |
Blood-Conservation Strategies in a Blood-Refusal Parturient with Placenta Previa and Placenta Percreta.
Topics: Adult; Bloodless Medical and Surgical Procedures; Combined Modality Therapy; Erythropoietin; Female; | 2016 |
Major obstetric hemorrhage.
Topics: Blood Component Transfusion; Combined Modality Therapy; Dinoprostone; Factor VIIa; Female; Fibrinoge | 2016 |
Tranexamic acid in the management of postpartum haemorrhage.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post | 1996 |
Tranexamic acid in the management of postpartum haemorrhage.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post | 1996 |
Tranexamic acid in the management of postpartum haemorrhage.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post | 1996 |
Tranexamic acid in the management of postpartum haemorrhage.
Topics: Adult; Blood Loss, Surgical; Cesarean Section; Critical Care; Female; Humans; Placenta Accreta; Post | 1996 |